November 16, 2015
AstraZeneca’s Tagriss approved in USA
US FDA has approved TAGRISSO for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer.
Pharmaceuticals, Biotechnology and Life Sciences
US FDA has approved TAGRISSO for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer.